DIABETOLOGY

METAFIN FORTE-0.2
(Glimepride 1mg + Metaformin 500mg + Voglibose 0.2mg Tablets)

Glimepiride + Metformin + Voglibose is a combination of three antidiabetic medicines: Glimepiride, metformin and voglibose. They work by different mechanisms to provide better control of blood sugar when single or dual therapy is not effective.
Glimepiride is a sulfonylurea which works by increasing the amount of insulin released by the pancreas to lower the blood glucose.
Metformin is a biguanide which lowers glucose production in the liver, delays glucose absorption from intestines and increases the body's sensitivity to insulin.
Voglibose is an alpha-glucosidase inhibitor which prevents breakdown of complex sugars into simple sugars such as glucose. This prevents the blood glucose levels from rising to very high levels after meals.

METAFIN- G1
( Glimipride 1mg + Metformin 500mg Tablets )

Glimepiride + Metformin is a combination of two antidiabetic medicines: Glimepiride and Metformin. Glimepiride is a sulfonylurea which works by increasing the amount of insulin released by the pancreas in order to lower the blood glucose. Metformin is a biguanide which works by lowering glucose production in the liver, delaying glucose absorption from intestines and increasing the body's sensitivity to insulin.

METAFIN- G2
( Glimipride 2mg + Metformin 500mg Tablets )

Glimepiride + Metformin is a combination of two antidiabetic medicines: Glimepiride and Metformin. Glimepiride is a sulfonylurea which works by increasing the amount of insulin released by the pancreas in order to lower the blood glucose. Metformin is a biguanide which works by lowering glucose production in the liver, delaying glucose absorption from intestines and increasing the body's sensitivity to insulin.

SITAFORD- 50
(Sitagliptin 50mg Tablets )

Sitagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amounts of certain natural substances that lower blood sugar when it is high
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar

SITAFORD MET
(Sitagliptin 50mg + Metformin 500mg Tablets )

Sitagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amounts of certain natural substances that lower blood sugar when it is high
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar
Metformin is a biguanide which lowers glucose production in the liver, delays glucose absorption from intestines and increases the body's sensitivity to insulin

Available Strengths: Etoricoxib 60mg+Thiocolchicoside 4mg and Etoricoxib 60mg+Thiocolchicoside 8mg

VILDAFORD -50
(Vildagliptin 50mg Tablets )

Vildagliptin is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired.2 By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are incretin hormones that promote insulin secretion and regulate blood glucose levels. Elevated levels of GLP-1 and GIP consequently results in improved glycaemic control. In clinical trials, vildagliptin has a relatively low risk of hypoglycaemia..

Available strength: 25mg, 50mg, 100mg

VILDAFORD MET
(Vildagliptin 50mg + Metformin 500mg Tablets )

Vildagliptin is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired.2 By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are incretin hormones that promote insulin secretion and regulate blood glucose levels. Elevated levels of GLP-1 and GIP consequently results in improved glycaemic control. In clinical trials, vildagliptin has a relatively low risk of hypoglycaemia